Study summary
A cisplatin-free pembrolizumab approach to saving the larynx missed its goal
65.1%alive without laryngectomy at 2 years, vs 59% historically
What was tested
Pembrolizumab with radiation, without cisplatin, aiming to cure locally advanced laryngeal cancer while keeping the voice box.
What they found
- 2-year survival without laryngectomy was 65.1%, not significantly better than the 59% historical benchmark.
- The larynx was preserved in 84.3% at 2 years.
What it means
Cisplatin with radiation remains the standard for larynx preservation; immunotherapy alone is not yet a substitute.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.